期刊文献+

HPLC法测定人血浆中伏立康唑浓度 被引量:3

Determination of Voriconazole in Human Plasma by HPLC
下载PDF
导出
摘要 目的建立一种快速、灵敏、准确的HPLC法测定人血浆中伏立康唑浓度,用于临床上该药的血药浓度监测。方法色谱柱:Agilent Eclipse XDB-C18(4.6 mm×150 mm,5μm),流动相:乙腈-水(含0.1%甲酸)(40∶60),流速:1.0ml.min-1,紫外检测波长:256 nm,内标:醋酸可的松,柱温:40℃,进样量:40μl。结果伏立康唑和醋酸可的松的保留时间分别为5.2 min和6.7 min;血浆中伏立康唑线性范围为0.1~10μg.ml-1(r=0.9999),定量下限为0.1μg.ml-1,日内、日间RSD分别<2.07%、4.20%,低、中、高3个浓度提取回收率分别为82.62%、84.26%和78.18%。结论本方法操作简便,结果准确,适用于临床伏立康唑的血药浓度监测。 Objective To establish a quick, sensitive and accurate HPLC method for the determination of voriconazole levels in human plasma. Methods Chromatography was performed on Agilent Eclipse XDB-C18 column (4.6 mm × 150 mm,5 μm), with acetonitrile-water (0.1% formic acid) (40: 60) as the mobile phase. The flow rate was 1.0 m] .min-1 and the detection wavelength was 256 nm. Cortisone acetate was used as the internal stand- ard. The column temperature was 40 ℃ and injection volume was 40 μl. Results Voriconazole and the internal standard were eluted at 5.2 min and 6.7 rain, respectively. The calibration curve was linear over the concentration range of 0.1-10 μg -ml - 1 ( r = 0. 9999) with the lower limit of quantitation (LLOQ) at 0.1 txg -ml -i. Intra- and inter-day RSD was below 2.07% and 4.20%, respectively. The extraction recovery of the low, medium and high concentration was 82.62% ,84.26% and 78.18%, respectively. Conclusion The HPLC method for determining the voriconazole level in plasma is simple, highly selective and sensitive.
出处 《解放军药学学报》 CAS 2013年第1期32-34,共3页 Pharmaceutical Journal of Chinese People's Liberation Army
关键词 伏立康唑 HPLC 血药浓度监测 voriconazole HPLC TDM
  • 相关文献

参考文献7

二级参考文献48

  • 1曹永兵,张磊,王彦,姜远英.伏立康唑及其临床应用[J].中国新药与临床杂志,2005,24(4):330-332. 被引量:48
  • 2黄成坷,邱相君,徐鹏,胡国新,代宗顺.酮康唑胶囊的人体生物等效性研究[J].中国抗生素杂志,2006,31(7):442-444. 被引量:2
  • 3南志成.高效液相色谱法测定人血浆中伏立康唑浓度[J].中国医院药学杂志,2006,26(7):836-839. 被引量:16
  • 4POTOSKI B A, BROWN J. The safety of voriconazole[ J]. Clin Infect Dos, 2002,35 (10) : 1273 - 1275. 被引量:1
  • 5Michael C,Teichert J ,Preiss R in human plasma and saliva Determination of voriconazole using high-performance liquid chromatography with fluorescence detection[J]. J Chroma togr B Analyt Technol Life Sci,2008,865(1-2) :74-80. 被引量:1
  • 6Mizutani T. PM frequencies of major CYPs in Asians and Caucasians[J]. Drug Metab Rev,2003,35(2-3) :99-106. 被引量:1
  • 7Smith J,Safdar N, Knasinski V, et al. Vorieonazole therapeutic drug monitoring[J]. Antimicrob Agents Chemother,2006, 50(4) : 1570-1572. 被引量:1
  • 8Pascual A,Calandra T,Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes[J]. Clin Infect Dis,2008, 46(2) ,201-211. 被引量:1
  • 9Jeu L, Piacenti FJ, Lyakhovetskiy AG, et al. Voriconazole[J]. Clin Ther, 2003, 25 (5):1321 -1381. 被引量:1
  • 10Kazuaki M, Kazuro I, kazuko A, et al. Correlation between voriconazole through plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes [J]. Int J Antimicrob Agents, 2009, 34 (1): 91- 94. 被引量:1

共引文献48

同被引文献17

引证文献3

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部